A Research Study for Latina Women With Breast Cancer
An e-Health Intervention to Improve Symptom Burden and Health-Related Quality of Life Among Hispanic Women Completing Active Treatment for Breast Cancer
1 other identifier
interventional
58
1 country
1
Brief Summary
The purpose of this study is to examine the feasibility and preliminary efficacy of a psychosocial eHealth intervention designed to improve hormone therapy adherence among Hispanic/Latinx women with breast cancer. Our proposed secondary outcomes are health-related quality of life and self-efficacy in managing hormone therapy side effects. The intervention components include breast cancer knowledge, hormone/endocrine therapy knowledge, stress awareness and management, social support, and enhanced communication and intimacy skills. The intervention will be delivered via a Smartphone application over a 12-week period. All participants will receive the intervention application (described below). Aside from using the Smartphone application for the recommended 12 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), 6-week follow-up, and 12-week follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2021
CompletedStudy Start
First participant enrolled
April 1, 2021
CompletedFirst Posted
Study publicly available on registry
April 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 25, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 7, 2023
CompletedNovember 8, 2023
November 1, 2023
1.6 years
March 31, 2021
November 7, 2023
Conditions
Outcome Measures
Primary Outcomes (10)
Acceptability of My Guide: Usefulness
To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.
T3 (immediately following 12 week intervention)
Acceptability of My Guide: Satisfaction
To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.
T3 (immediately following 12 week intervention)
Acceptability of My Guide: Learnability
To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.
T3 (immediately following 12 week intervention)
Acceptability of My Guide: Usability
To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.
T3 (immediately following 12 week intervention)
Demand of My Guide: Recruitment Rate
We assess demand of the My Guide application through study recruitment. Based on previous psychosocial and behavioral studies in oncology, an 70% recruitment rate is considered an adequate level of demand.
12 weeks
Demand of My Guide: Retention Rate
Another way we assess demand of the My Guide application is through participant retention. Based on previous psychosocial and behavioral studies in oncology, an 70% retention rate is considered an adequate level of demand.
12 weeks
Participant use of My Guide: Number of Login's
We assess participant use of the My Guide application by examining the number of participant logins to the web-based application.
12 weeks
Participant use of My Guide: Duration of Usage
We assess participant use of the My Guide application by examining the duration participant time spent on the website. Based on previous psychosocial and behavioral studies in oncology, an average of 8 hours of use is considered an adequate level of engagement.
12 weeks
Participant use of My Guide: Content Accessed
We assess participant use of the My Guide application by examining the type of content accessed by participants on the website.
12 weeks
Change in Medication adherence will be assessed primarily with the Adherence to Refills and Medication Scale (ARMS).
The ARMS (Adherence to Refills and Medications Scale) survey is a previously validated patient-report measure of barriers to medication adherence and adherence-related behavior.
T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)
Secondary Outcomes (2)
Change in Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy (FACT-G7)
T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)
Change in Patient Self-Efficacy in managing side effects is measured using the PROMIS Self Efficacy for Managing Symptoms
T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)
Study Arms (1)
"My Guide" (psychoeducation & self management program)
EXPERIMENTALSmartphone-based program plus standard clinical care.
Interventions
12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
Eligibility Criteria
You may qualify if:
- Female
- Diagnosis of breast cancer, non-metastatic, stage 0-III (A, B, or C)
- Receiving or received endocrine/hormone therapy within the last 3 years (36 months)
- At least 18 years of age
- Able to speak and read English or Spanish
- Able to provide informed consent
- Self-identify Hispanic/Latina ethnicity
You may not qualify if:
- Stage IV or metastatic
- Visual, hearing, voice, or motor impairment that would prevent completion of study procedures
- Diagnosis of an unmanaged psychotic disorder, bipolar disorder, dissociative disorder, or other diagnoses for which participation in this trial is either inappropriate or dangerous - this includes patients who have a life-threatening illness (e.g., end-stage kidney disease) or diagnosis of a chronic disease that is associated with a major functional impairment (e.g., fibromyalgia)
- Illicit substance or alcohol dependence
- Suicidal ideation, plan, intent
- Alzheimer's, dementia, or history of stroke
- Scheduled reconstruction surgery within 1 month of any study procedures or involvement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Northwestern University
Chicago, Illinois, 60611, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 31, 2021
First Posted
April 27, 2021
Study Start
April 1, 2021
Primary Completion
October 25, 2022
Study Completion
November 7, 2023
Last Updated
November 8, 2023
Record last verified: 2023-11